Home › Research › Cognitive tests and assessment
Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease
Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ.. Neurochemistry international, 2001-11-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Postmortem demonstration of increased expression of biologically active S100B in Alzheimer's disease (AD) and its relation to progression of neuropathological changes across the cortical regions suggests involvement of this astrocytic cytokine in the pathophysiology of AD. The hypothesis that the overexpression of S100B in Alzheimer brain is related to the progression of clinical symptoms was addressed in living persons by measuring S100B concentrations in cerebrospinal fluid (CSF) from AD patients with a broad range of clinical dementia severity and from healthy older persons. The effect of normal aging on CSF S100B concentrations also was estimated.
What this study adds
Evidence grade: Low
This study measured S100B levels in cerebrospinal fluid from 68 Alzheimer's patients and 25 healthy older people to test whether the protein relates to symptom progression. It is biomarker research, not evidence about treating, curing or preventing the disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Peskind, E. R., Griffin, W. S., Akama, K. T., Raskind, M. A., & Van Eldik, L. J. (2001). Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochemistry international. https://doi.org/10.1016/s0197-0186(01)00048-1
Vancouver
Peskind ER, Griffin WS, Akama KT, Raskind MA, Van Eldik LJ. Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease. Neurochemistry international. 2001. doi:10.1016/s0197-0186(01)00048-1. PMID: 11578776.
BibTeX
@article{peskind2001-11578776,
author = {Peskind, E. R. and Griffin, W. S. and Akama, K. T. and Raskind, M. A. and Van Eldik, L. J.},
title = {{Cerebrospinal fluid S100B is elevated in the earlier stages of Alzheimer's disease}},
journal = {Neurochemistry international},
year = {2001},
doi = {10.1016/s0197-0186(01)00048-1},
pmid = {11578776},
url = {https://doi.org/10.1016/s0197-0186(01)00048-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The hypothesis that the overexpression of S100B in Alzheimer brain is related to the progression of clinical symptoms was addressed in living persons by measuring S100B concentrations in cerebrospinal fluid (CSF) from AD patients with a broad range of clinical dementia severity and from healthy older persons.
- The effect of normal aging on CSF S100B concentrations also was estimated.
- CSF S100B did not differ between all 68 AD subjects (0.98+/-0.09 ng/ml (mean+/-S.E.M.)) and 25 healthy older subjects (0.81+/-0.13 ng/ml).
- When AD subjects were divided into mild/moderate stage and advanced stage clinical dementia severity by the established Clinical Dementia Rating Scale (CDR) criteria, S100B was significantly higher in the 46 mild/moderate stage AD subjects (1.17+/-0.11 ng/ml) than in either the 22 advanced stage AD subjects (0.60+/-0.12 ng/ml) or the healthy older subjects.
Why it matters
This study measured S100B levels in cerebrospinal fluid from 68 Alzheimer's patients and 25 healthy older people to test whether the protein relates to symptom progression. It is biomarker research, not evidence about treating, curing or preventing the disease.
Study details
- Evidence strengthLow
How this study scored 45/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurochemistry international) |
| Journal's citation record | 2 / 4 | Neurochemistry International: journal h-index 170 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2001 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 215 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 8.0 citations a year over 27 year(s) since 2001 |
| Impact for its field and year | 2 / 6 | Cited 2.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 11 other studies in this library |
| Still being cited | 2 / 4 | Cited 21 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Linda J. Van Eldik: h-index 99 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | University of Washington: institution h-index 3,540 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 11578776) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 45 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
11 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.